KOD
Market read
No new filing conclusion is available. 0 of 17 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
Invalidation: The isolated read changes if KOD's group or a disclosed connection begins moving with it.
Research brief
No new filing conclusion is available. 0 of 17 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
Company research
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
No qualifying supportive evidence was identified.
No credible peer-relative valuation comparison is available yet.
What management says matters
“We use foreign currency forward contracts to protect against changes in anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates, primarily associated with non-functional currency denominated expenses.”10-Q · May 7, 2026 ↗
“Facilities and other research and development expenses decreased $1.4 million during the three months ended March 31, 2026, as compared to the same period in 2025, primarily due to a reduction in the amount of rent expense allocated to R&D following the suble…”10-Q · May 7, 2026 ↗
“General and Administrative Expenses General and administrative expenses decreased $4.2 million during the three months ended March 31, 2026, as compared to the same period in 2025, due to lower stock compensation expense as we are no longer recognizing expens…”10-Q · May 7, 2026 ↗
Valuation discipline
Price/sales — · EV/sales —. Comparisons use only industry-matched filing peers.
Fewer than 4 annual revenue periods; too little history to scaffold scenarios.
Price action
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
Jodie has not returned a relevant primary source or news item for KOD. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
Jodie has not yet found a suitable current-versus-prior filing comparison for KOD. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
“Several of our competitors have commercially approved products for the treatment of retinal diseases that we are pursuing or may pursue in the future, including Roche, Regeneron and Novartis for the treatment of wet AMD, DME, DR and RVO.”
“6 Regeneron’s Eylea HD is a major competitive product, with FDA approvals across wet AMD, DME, DR and RVO.”
Depended on by
“We also face competition from late-stage sustained release VEGF receptor tyrosine kinase 11 inhibitor programs at EyePoint Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
KOD is currently a Follower in the organic co-movement group Energy Infrastructure & Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for KOD; it is not active in the latest market snapshot.
Context history
No durable theme membership has been observed for this name yet.